The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.

IF 12.8 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2026-10-01 DOI:10.1002/alz.71794

Douglas Barthold, Julie Zissimopoulos, Anirban Basu, Bryan Tysinger

{"title":"The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.","authors":"Douglas Barthold, Julie Zissimopoulos, Anirban Basu, Bryan Tysinger","doi":"10.1002/alz.71794","DOIUrl":null,"url":null,"abstract":"Introduction: Diabetes is associated with elevated risk of Alzheimer's disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited, especially for persons at highest risk of ADRD.Methods: Using 10 years of data on Americans aged 51 and older with diabetes, we employed dynamic microsimulation to analyze the impact of increased utilization of glucagon-like peptide 1 receptor agonists (GLP1s) and sodium-glucose cotransporter-2 inhibitors (SGLT2s) on ADRD incidence.Results: Over 10 years, utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 ADRD cases. The risk reduction is largest for Black and Hispanic individuals and individuals with HbA1c > 8.Discussion: This study shows that improving diabetes management can lead to large reductions in ADRD risk. Improved adherence and access for those with higher HbA1c and higher risk of ADRD will have the largest benefit.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 10","pages":"e71794"},"PeriodicalIF":12.8000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655229/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.71794","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Diabetes is associated with elevated risk of Alzheimer's disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited, especially for persons at highest risk of ADRD.

Methods: Using 10 years of data on Americans aged 51 and older with diabetes, we employed dynamic microsimulation to analyze the impact of increased utilization of glucagon-like peptide 1 receptor agonists (GLP1s) and sodium-glucose cotransporter-2 inhibitors (SGLT2s) on ADRD incidence.

Results: Over 10 years, utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 ADRD cases. The risk reduction is largest for Black and Hispanic individuals and individuals with HbA1c > 8.

Discussion: This study shows that improving diabetes management can lead to large reductions in ADRD risk. Improved adherence and access for those with higher HbA1c and higher risk of ADRD will have the largest benefit.

查看原文本刊更多论文

改善获得糖尿病药物对阿尔茨海默病和相关痴呆风险的影响。

糖尿病与阿尔茨海默病和相关痴呆（ADRD）的风险升高相关。药物治疗的疾病管理可以减轻这种增加的风险，但糖尿病治疗的可及性和使用是有限的，特别是对ADRD风险最高的人。方法：利用美国51岁及以上糖尿病患者10年的数据，我们采用动态微观模拟来分析胰高血糖素样肽1受体激动剂（GLP1s）和钠-葡萄糖共转运蛋白2抑制剂（SGLT2s）使用增加对ADRD发病率的影响。结果：在10年内，糖尿病和HbA1c患者使用glp1和SGLT2s可避免76,000-201,000例ADRD。黑人和西班牙裔患者以及HbA1c为bb0.8的患者的风险降低幅度最大。讨论：这项研究表明，改善糖尿病管理可以导致ADRD风险的大幅降低。对于HbA1c较高和ADRD风险较高的患者，改善依从性和可及性将是最大的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.